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Abstract
Background: The functional polymorphism (rs1800566) in the NQO1 gene, a 609C.T substitution, leading to proline-to-
serine amino-acid and enzyme activity changes, has been implicated in cancer risk, but individually published studies
showed inconclusive results.
Methodology/Principal Findings: We performed a meta-analysis of 20 publications with a total of 5,491 cases and 5,917
controls, mainly on gastrointestinal (GI) cancers. We summarized the data on the association between the NQO1 609C.T
polymorphism and risk of GI cancers and performed subgroup analyses by ethnicity, cancer site, and study quality. We
found that the variant CT heterozygous and CT/TT genotypes of the NQO1 609 C.T polymorphism were associated with a
modestly increased risk of GI cancers (CT vs. CC: OR=1.10, 95% CI=1.01 – 1.19, Pheterogeneity=0.27, I
2=0.15; CT/TT vs. CC:
OR=1.11, 95%CI=1.02 – 1.20, Pheterogeneity=0.14; I
2=0.27). Following further stratified analyses, the increased risk was only
observed in subgroups of Caucasians, colorectal cancer in Caucasians, and high quality studies.
Conclusions: This meta-analysis suggests that the NQO1 609T allele is a low-penetrance risk factor for GI cancers. Although
the effect on GI cancers may be modified by ethnicity and cancer sites, small sample seizes of the subgroup analyses
suggest that further larger studies are needed, especially for non-colorectal GI cancers in Caucasians and GI cancers in
Asians.
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Introduction
Gastrointestinal (GI) cancers are the common malignant tumors
in the world [1,2], of which colorectal cancer is the third most
common cancer in males and the second in females, with over 1.2
millions of new cases and 608,700 deaths occurred in 2008 [2]. It
was estimated that cancers of the esophagus, stomach, colorectum,
and liver accounted for 26.4% (3.4 millions) of the total new
cancer cases and 32.8% (2.5 millions) of the total cancer deaths in
2008 worldwide [2]. Although the causes of these cancers are
complex and heterogeneous, chronic inflammation, cigarette
smoking, heavy alcohol drinking, and poor dietary pattern are
generally considered possible risk factors for these cancers
[3,4,5,6,7,8,9,10,11,12,13]. In addition, numerous case-control,
family-based and twin studies have shown that inherited genetic
factors have played an important role in susceptibility to these
diseases [12,13,14,15,16,17]. Recent genome-wide association
studies have also identified some susceptible loci harboring
common single nucleotide polymorphisms (SNPs) for risk of GI
cancers, suggesting that the low-penetrance genes are also involved
in the etiology of these diseases [18,19,20,21,22].
NAD(P)H:quinone oxidoreductase 1 (NQO1) is an obligate
two-electron reductase, which reduces reactive quinones to less
reactive and less toxic hydroquinones. The quinones are mainly
derived from endogenous quinones, such as vitamin E quinone
and ubiquinone, and exogenous quinones, such as exhaust gas,
cigarette smoke or diet [23,24]. This two-electron reduction
prevents the formation of semiquinones and highly reactive
oxygen species (ROS), thus protecting cells against oxidative
stress, cytotoxicity, and mutagenicity [25]. In addition to its
catalytic role in quinones, NQO1 has been reported to show
superoxide scavenging activity and protective activity against
procarcinogenic benzenes [26,27]. Notably, both in vivo and in vitro
studies have demonstrated that NQO1 regulates the stability of the
tumor suppressors p53 and p73, protecting them from 20S
proteasomal degradation, which is important for eliminating
damaged cells that are prone to cancer development [28,29,
30,31]. Therefore, NQO1 is considered an important defense
against cancer [25,31].
The NQO1 gene is located on chromosome 16q22.1, spanning
,17.2 kb and consisting of 6 exons and 5 introns [32]. To date,
there have been 270 SNPs identified in the NQO1 gene (http://
www.ncbi.nlm.nih.gov/SNP). The most extensively studied SNP
of NQO1 is a C-to-T transition at nucleotide position 609 in exon 6
(dbSNP ID: rs1800566, 609C.T; Figure 1), which results in a
proline-to-serine amino-acid substitution at codon 187 (Pro187Ser)
in the protein. Genotype-phenotype studies of the NQO1 609C.T
polymorphism showed that the variant T allele was associated with
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primary human tissues [24,33,34,35]. Furthermore, there is a clear
allele dosage effect of the NQO1 609T genotypes on NQO1
enzymatic activity, with the homozygotes (TT) having the lowest,
the heterozygotes (CT) having the intermediate, and the wild-type
homozygotes (CC) having the highest NQO1 enzyme activity
[33,36,37,38]. Decreased NQO1 enzymatic activity is caused by
increased polyubiquination and proteosomal degradation of the
mutant NQO1 protein [39]. Altered expression of NQO1 protein
has been observed in liver, colon, esophagus, stomach, and
pancreas cancers [40,41,42,43,44,45]. Furthermore, the TT
genotype of the NQO1 609C.T polymorphism was associated
with reduced NQO1 protein expression in tumor tissues from a
subset of GI cancer patients (cardiac carcinoma, gastric adeno-
carcinoma, esophageal adenocarcinoma, and esophageal squa-
mous cell carcinoma) [43,45]. Because of this SNP’s functional
consequence, many epidemiological studies have examined the
effect of the NQO1 609C.T polymorphism on risk of GI cancers,
including cancers of the esophagus, stomach, colorectum,
pancreas, and liver. However, the reported genetic effects varied
across the published studies, and a clear impact of this SNP on
cancer risk is also limited by the insufficient statistical power of
these individual studies with a relatively small sample size.
Therefore, we performed a meta-analysis of published data to
evaluate the influence of the NQO1 609C.T polymorphism on
the risk of GI cancers.
Materials and Methods
Identification and eligibility of relevant studies
Using the PubMed search engine, we searched Medline
databases, on the association of NQO1 609C.T polymorphism
(rs1800566) with the risk of GI cancers (defined as cancers of the
esophagus, stomach, colorectum, pancreas, gallbladder, liver and
small/larger bowel cancer), which had been published up to
October 6, 2011 with a limit to human studies in English
language. The following keywords were used: ‘NAD(P)H Dehy-
drogenase (Quinone)’ or ‘NQO1’, ‘polymorphism’, ‘variant’, and
in combination with ‘gastrointestinal/aerodigestive tract cancers’,
or‘esophagealcancer’, ‘gastric/stomach’ cancer,‘colorectal/colon/
rectum cancer’, ‘ pancreatic cancer’, ‘liver cancer’, ‘hepatocellular
carcinoma’, ‘gallbladder cancer’, and ‘small/larger bowel cancer’.
In addition, the references cited in the retrieved studies were also
reviewed manually to identify publications on the same cancer type.
If studies from the same study group had overlapped subjects, the
most recent or largest study was included in the final analysis.
Human population-based or hospital-based association studies were
included in this meta-analysis, if they met all the following criteria:
(1) an independent, unrelated case-control, nested case-control, or
cohort study, (2) the NQO1 609C.T polymorphism was deter-
mined,(3)the outcome was GI cancers, (4)thereweresufficientdata
for calculating an odds ratio (OR) with 95% confidence interval
(CI), and (5) the study was reported in English. Exclusion criteria
were: (1) duplicate data, (2) abstract, case report, comment, review
andeditorial, (3)no sufficient genotyping data were provided, (4)the
outcome was benign tumors, precancerous lesions, and adenomas,
and (5) family-based study.
Data extraction
Two reviewers (HY and HL) independently reviewed the
articles and extracted the data from all eligible publications
according to the criteria listed above. The following information
was recorded for each study: first author, year of publication,
country or region of origin, ethnicity, cancer type, number of cases
and controls, number of cases and controls by genotype, source of
control group (population-based or hospital-based), genotyping
methods, minor allele frequency in controls, method for matching
controls to cases. Any discrepancies between the two investigators
were resolved by discussion and consultation with a third reviewer
(LW).
Quality score assessment
The quality of included studies was independently assessed by
the same two reviewers using the quality assessment criteria, which
was modified from previously published meta-analysis of molec-
Figure 1. NQO1 gene structure and its function. A. NQO1 gene structure and NQO1 609C.T polymorphism location. B. The multiple functions of
NQO1. As depicted, NQO1 performs multiple functions within the cell, including two-electron reduction of quinones and their derivatives,
stabilization of p53 and other tumor suppressors against proteasomal degradation, and scavenging of superoxide. NQO1 has also been implicated in
maintaining microtubule integrity.
doi:10.1371/journal.pone.0030566.g001
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related to both traditional epidemiological considerations and
cancer genetic issues in terms of quality of the studies:
representativeness of the cases, representativeness of the controls,
ascertainment of GI cancers, control selection, genotyping
examination, response rate, and total sample size. The criteria
are described in detail in Table S1, and the scores were defined
as 1 to 3 points given to each component or 0 if absent or the study
with a sample size of less than 200. A final quality score was
obtained by summation of each component giving a range from 0
(the lowest) to 15 (the highest). Studies scoring,8 were classified as
low quality, and those $8 as high quality. Disagreements were
resolved by consultation with the third reviewer.
Statistical analysis
Deviation of genotype frequencies of the NQO1 609C.T
polymorphism in control subjects from Hardy-Weinberg equilib-
rium (HWE) was tested by using the Chi-square goodness of fit,
and a P value,0.05 was considered significant. Odds ratio (OR)
and corresponding 95% confidence interval (95% CI) were used to
estimate the association between the NQO1 609C.T polymor-
phism and cancer risk. We estimated the risk for the variant
homozygous TT and heterogeneous CT genotypes, compared
with the wild-type homozygous CC genotype, and then for CT/
TT vs. CC and TT vs. CC/CT, assuming both dominant and
recessive effect models, respectively. The heterogeneity across
studies was assessed with the Q test, and the heterogeneity was
considered significant when a P-value,0.1 for the Q statistic [48].
If the heterogeneity was not significant, the fixed-effects model was
used to estimate the summary OR and 95% CI; Otherwise, the
random-effects model was used [49]. We also calculated the I
2
index, which can quantify the degree of heterogeneity in a the
meta-analysis [50]. The potential source of heterogeneity across
studies was explored by stratification and meta-regression analyses.
Stratified analyses were conducted by several study characteristics,
such as ethnicity, type of cancers (if one cancer type contains less
than two studies, it was merged into the ‘other cancers’ group),
and quality score of studies (quality score,8 and $8). In addition,
the studies investigating multiple types of cancers or multiple
ethnicities were separated into groups for the subgroup analysis.
Both Begg’s and Egger’s tests [51,52] were used to test for
publication bias. A P-value,0.1 was used as an indication for the
presence of potential publication bias. Sensitivity analyses were
conducted by including and excluding studies not in HWE, and by
removing one study at a time to assess the influence of individual
studies on the pooled ORs, respectively. All analyses were
performed by using Review Manager (v.5.0; Oxford, England)
and Stata software (version 8.2; Stata Corp LP, College Station,
TX, USA). In addition, for each statistically significant association,
we estimated the false positive report probability (FPRP) using the
method described by Wacholder et al [53] to evaluate the
robustness of the findings. Wacholder et al suggested that
estimating statistical power based on the ability to detect an OR
of 1.5 (or 0.67=1/1.5 for an OR less than 1.0), with an alpha level
equal to the observed P-value [53]. Because a single nucleotide
polymorphism usually shows a relatively small effect size (i.e.,
OR,1.5), we presented results for an OR of 1.2. An FPRP less
than 0.2 was considered as a noteworthy association [53].
Results
Characteristics of all included studies
As of October 6, 2011, we had identified 29 potentially eligible
studies that have investigated the association between the NQO1
609C.T polymorphism and risk of GI cancers. After retrieving
the full text of these 29 articles, we excluded 9 articles because of
the following reasons: one reported the association between the
NQO1 609C.T SNP and H. pylori seropositivity [54]; one did not
focus on the NQO1 609C.T but on NQO1 R139W SNP
(rs4986998) [55]; three were for the association between the
NQO1 609C.T SNP and colorectal adenoma [56,57,58]; two
were for the correlation between the NQO1 609C.T genotypes
and NQO1 activity [59] or telomere length [60]; two were for
review or meta-analysis articles [61,62]. In addition, the Caucasian
control group (252 Caucasian controls) in the study by Zhang et al.
[45] had overlapped subjects used in the study by Sarbia et al.
[43], and the esophageal cancer patients (193 cases) in the study by
Zhang et al. [63] were also overlapped with those in the same
author’s study [45]. Therefore, these 252 Caucasian controls and
193 esophageal cancer patients were excluded to avoid double
counting in our meta-analysis. The flow chart in Figure 2
summarizes this literature review process.
Overall, data from 20 publications with 5,491 cases and
5,917 controls were available for our meta-analysis. Main
characteristics of the included publications are presented in
Table 1. Among the 20 publications, four studies were for
esophageal cancer [45,64,65,66], one for gastric cancer [67],
nine for colorectal cancer [55,59,68,69,70,71,72,73,74,75,76],
two for pancreatic cancer [77,78], one for liver cancer [79],
and three for multiple types of GI cancers [43,63,80]. Of all
studies, 11 studies were conducted in Caucasian populations
[43,65,66,68,71,72,73,74,75,76,77,78], seven in Asian populations
[63,64,67,69,70,79,80], and two in multiple populations [45,76].
Polymerase chain reaction (PCR)-restriction fragment length
polymorphism (RFLP) method was used to determine the
genotype in all the included studies except for one by
Mohelnikova-Duchonova et al. [78], in which the TaqMan Assay
was used. The genotype frequency distributions of the NQO1
609C.T polymorphism in controls in 19 of 20 included studies
were in agreement with HWE. The HWE test in the study by
Lafuente et al. was not mentioned [72]; we also could not perform
the HWE test for the subjects (either cases or controls) in that
study, because only the total number of the combined genotypes
(TT vs. CT/CC) was available. Therefore, this study was included
in the analysis for the recessive model but not for other genetic
models. Quality scores for the individual studies ranged from 4 to
13, with 60.0% (12 of 20) of the studies being classified as high
quality ($8).
Frequency of the NQO1 609 C.T polymorphism in
control populations
Of 5,917 control subjects included in this meta-analysis, 3622
were Caucasians and 2295 were Asians. The frequency distribu-
tions of the genotypes of the NQO1 609 C.T polymorphism were
different between these two ethnic groups. The frequencies of the
TT, CT, and CC genotypes were 3.1%, 28.2%, and 68.7%,
respectively, in Caucasians and 13.1%, 44.7%, and 42.2% in
Asians, respectively (Table 2).
Association between the NQO1 609C.T polymorphism
and the risk of GI cancers
Overall, as shown in Table 3, compared to the wild-type CC
homozygous genotype, the CT heterozygous genotype was
significantly associated with a modestly increased risk for GI
cancers (CT vs. CC: OR=1.10, 95% CI=1.01 – 1.19). A main
effect also was significant in the dominant model (CT/TT vs. CC:
OR=1.11, 95% CI=1.02 – 1.20) (Figure 3). There was no
NQO1 Polymorphism and Gastrointestinal Cancers
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and I
2=0.15 for CT vs. CC; Pheterogeneity=0.14 and I
2=0.27 for
CT/TT vs. CC). We found similar effects in the homozygous
comparison (TT vs.CC: OR=1.20, 95% CI: 0.96 – 1.50) and in
the recessive model comparison (TT vs. CT/CC: OR=1.22, 95%
CI: 0.98 to 1.51). However, these effects did not reach statistical
significance. A modest heterogeneity among the studies was
observed (Pheterogeneity=0.09 and I
2=0.32 for TT vs. CC;
Pheterogeneity=0.06 and I
2=0.36 for TT vs. CT/CC). Subsequent
sensitivity analyses were performed by removing the individual
study sequentially, and we found that all but one Japanese study by
Hamajima et al. [80] slightly influenced the overall pooled ORs.
After exclusion of this study, a significant increased risk was found
in the homozygous comparison (TT vs.CC: OR=1.27, 95% CI:
1.03 – 1.47) or in the recessive model comparison (TT vs. CT/CC:
OR=1.29, 95% CI: 1.05 – 1.59), and the heterogeneity among
the studies was not significant (Pheterogeneity=0.18 and I
2=0.23 for
TT vs. CC; Pheterogeneity=0.20 and I
2=0.20 for TT vs. CT/CC),
suggesting that this study may contribute to the observed
heterogeneity across studies.
In the stratified analysis by ethnicity, as shown in Table 3,
significantly elevated cancer risks were found among Caucasians in
the heterozygous genotype comparison (CT vs. CC: OR=1.13,
95% CI: 1.01 –1.26, Pheterogeneity=0.24 and and I
2=0.22) and the
dominant model comparison (CT/TT vs. CC: OR=1.14, 95% CI
5 1.02 – 1.26, Pheterogeneity=0.26 and I
2=0.27), but not in the
homozygous genotype comparison (TT vs. CC: OR=1.20, 95%
CI: 0.91 – 1.58, Pheterogeneity=0.27 and I
2=0.19) and the recessive
model comparison (TT vs. CT/CC: OR=1.25, 95% CI: 0.96 –
1.62, Pheterogeneity=0.20 and I
2=0.25). No significant heterogeneity
wasobserved forall thegenetic mode1comparisons.Theleave-one-
out sensitivity analysis found that no single study dramatically
influenced the overall pooled ORs (data not shown). In Asians, no
significant association between the NQO1 609C.T polymorphism
and the risk of GI cancers was found for all variant genotypes (CT
vs.CC: OR=1.07, 95% CI: 0.94 – 1.23, Pheterogeneity=0.43 and
I
2=0.0; TT vs.CC: OR=1.25, 95% CI: 0.90 – 1.73, Pheterogeneity
=0.05 and I
2=0.50), the dominant model (CT/TT vs. CC:
OR=1.07, 95% CI: 0.94 – 1.26, Pheterogeneity=0.17 and I
2=0.32)
and the recessive model (TT vs. CT/CC: OR=1.22, 95% CI: 0.90
– 1.21, Pheterogeneity=0.27 and I
2=0.52). However, the leave-one-
out sensitivity analysis showed that after removing the study by
Hamajima et al. [80], the heterogeneity among studies diminished,
and a significant association was found in the recessive model (TT
vs.CT/CC: OR=1.36, 95% CI: 1.02 – 1.81, Pheterogeneity=0.23
and I
2=0.26). In further stratification analysis by cancer site
(Table 3), a modestly significant increased risk was found for the
colorectal cancer under the dominant model in Caucasians (CT/
TTvs.CC:OR=1.13,95%CI:1.00 –1.28,Pheterogeneity=0.34 and
I
2=0.11). However, no significant association was observed for
other cancer sites either in Caucasians or in Asians. The leave-one-
out sensitivity analysis showed that no single study dramatically
influenced the overall pooled ORs (data not shown).
We also performed subgroup analysis by quality score of studies
(Table 3). We found that the CT heterozygous genotype was
significantly associated with a modestly increased risk for GI
cancers, compared to the wild-type homozygous genotype (CC) in
the studies with high quality score ($8.0) (CT vs.CC: OR=1.10,
95% CI: 1.00 – 1.22; Pheterogeneity=0.27 and I
2=0.18), and such
an effect was also found in the dominant genetic model (CT/TT
Figure 2. The flow chart of the included studies in the meta-analysis.
doi:10.1371/journal.pone.0030566.g002
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I
2=0.15). Similar effects were also found for the homozygous
genotype comparison (TT vs.CC: OR=1.13, 95% CI: 0.92 –
1.39; Pheterogeneity=0.48 and I
2=0.0) and for the recessive genetic
model comparison (TT vs.CT/CC: OR=1.17, 95% CI: 0.96 –
1.41; Pheterogeneity=0.36 and I
2=0.08), though they did not reach
statistical significance. In the subgroup of low quality studies, no
significant association between the NQO1 609C.T polymorphism
and the risk of GI cancers was observed. Sensitivity analyses
showed that no single study influenced quantitatively the overall
pooled ORs (data not shown).
Evaluation of heterogeneity
In the present study, we used the Q test and the I
2 index to
evaluate the heterogeneity across studies. As shown in Table 2,
although the Q test showed that there was no significant
heterogeneity in some overall comparisons and subgroup analyses,
the I
2 index suggested that a low to high heterogeneity across
studies presented in most of comparisons. We assessed heteroge-
neity across studies by ethnicity, cancer site, and quality of studies,
and found that they did not contribute the heterogeneity observed
across the studies in the overall meta-analysis (TT vs.CC:
t=20.24, P=0.815 for ethnicity, t=0.02, P=0.988 for cancer
sites, and t=0.39 8, P=0.703 for quality of studies; TT vs.CT/
CC: t=0.00, P=1.000 for ethnicity, t=20.29, P=0.773 for
cancer sites, and t=0.29, P=0.777 for quality of studies). These
factors were also not found to contribute to the heterogeneity
across studies in some of the subgroup analysis (data not shown).
Together with the results from the leave-one-out sensitivity
analysis as mentioned above, the study by Hamajima et al. could
Table 1. Characteristics of studies included in the meta-analysis.
First author
(Reference No.) Year Country Cancer type Ethnicity
No. of cases/
controls
Type of case-control
study
Genotyping
method
Quality
Score P-value
a
Marjani (64) 2010 Iran esophagus Asian 93/50 Hospital-based PCR-RFLP 5 0.47
Martino (65) 2007 United
Kingdom
esophagus Caucasian 141/93 Hospital-based PCR-RFLP 5 0.99
Rahden (66) 2004 German esophagus Caucasian 140/260 Hospital-based PCR-RFLP 4 0.17
Sarbia (43) 2003 German esophagus,
stomach, etc
Caucasian 384/252 Hospital-based PCR-RFLP 6 0.60
Zhang (45) 2003 German esophagus Mixed 450/393 Hospital-based PCR-RFLP 9 0.77
Zhang (63) 2003 China stomach,
esophagus
Asian 124/165 Hospital-based PCR-RFLP 7 0.39
Hamajima (80) 2002 Japan esophagus,
colorectum,
stomach, etc.
Asian 391/640 Hospital-based PCR-RFLP 7 0.17
Malik (67) 2010 India stomach Asian 108/195 Hospital-based PCR-RFLP 5 0.31
Sachse (75) 2002 United
Kingdom
colorectum Caucasian 490/593 Population-based PCR-RFLP 11 0.56
Hlavata (68) 2010 Czech colorectum Caucasian 495/495 Hospital-based PCR-RFLP 10 0.85
Sameer (69) 2010 India colorectum Asian 86/160 Hospital-based PCR-RFLP 8 0.45
Nisa (70) 2010 Japan colorectum Asian 684/777 Hospital-based PCR-RFLP 13 0.07
Begleiter (76) 2006 Canada colorectum Mixed 280/327 Hospital-based PCR-RFLP 9 0.29
van der Logt (71) 2006 New Zealandcolorectum Caucasian 369/415 Population-based PCR-RFLP 8 0.95
Harth (73) 2000 German colorectum Caucasian 323/205 Population-based PCR-RFLP 9 0.79
Mitrou (57) 2002 United
Kingdom
colorectum Caucasian 206/345 Hospital-based PCR-RFLP 9 0.96
Lafuente (72)
b 2000 Spain colorectum Caucasian 247/296 Hospital-based PCR-RFLP 8 -
Mohelnikova-
Duchonova (78)
2010 Czech pancreas Caucasian 235/265 Hospital-based TaqMan assay 8 0.80
Bartsch (77) 1998 German pancreas Caucasian 81/76 Hospital-based PCR-RFLP 5 0.27
Akkiz (79) 2010 Turkey liver Asian 167/167 Hospital-based PCR-RFLP 8 0.81
aP-value of the chi-square goodness of fit test for Hardy-Weinberg equilibrium (HWE) in controls.
bthe HWE test can not be conducted because only the total number of genotypes (TT vs. CT/CC) was available, and the HWE test was not mentioned in this study.
doi:10.1371/journal.pone.0030566.t001
Table 2. The genotype frequencies of the NQO1 609C .T
polymorphism in controls in different ethnic groups.
Ethnic group
Number of
controls Genotype (%)
CC CT TT
Caucasians
a 3326 2286 (68.7) 937 (28.2) 103 (3.1)
Asians 2295 968 (42.2) 1027 (44.7) 300 (13.1)
P-value
b 0.007 0.005 0.007
aThe study by Lafuente et al was excluded when calculating the genotype
frequency because the numbers for the CC and TT genotypes were not
provided in this study.
bTwo-side Student’s t test within the stratum.
doi:10.1371/journal.pone.0030566.t002
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in this meta-analysis.
Publication bias
Both Begg’s and Egger’s tests were performed to evaluate the
publication bias of the included studies. The shape of the funnel
plots did not reveal any evidence of obvious asymmetry for all
genetic models in the overall meta-analysis (Figure 4). The Begg’s
test and Egger’s test did not present any significantly statistical
evidence of publication bias for any of the genetic models (CT
vs.CC: PBegg=0.529 and PEgger=0.369, TT vs.CC: PBegg=0.726
and PEgger=0.690, CT/TT vs.CC: PBegg=1.000 and PEg-
ger=0.671, and TT vs.CT/CC: PBegg=0.626 and PEgger=0.700.)
Neither funnel plots nor Begg’s and Egger’s tests detected any
obvious evidence of publication bias in the subgroup analyses for
all genetic models (data not shown).
Finally, because many subgroup comparisons were conducted,
we calculated false positive report probability (FPRP) for each
statistically significant result. As shown in Table 4, with the
assumption of a moderate prior probability of 0.1 and the OR for
the specific genotype was 1.2, the FPRP values for the significant
findings in the heterozygous genotype comparison (CT vs. CC)
and the dominant model (CT/TT vs. CC) in all subjects, and in
the dominant model in Caucasians (CT/TT vs. CC) were 0.138,
0.074, 0.099, respectively. However, greater FPRP values were
observed for other significant associations between the NQO1
609C.T polymorphism and risk of GI cancers.
Discussion
In the present meta-analysis with 5,491 cases and 5,917
controls, the variant CT heterozygous genotype and the combined
CT/TT genotype of the NQO1 609 C.T polymorphism was
found to be associated with a modestly increased risk of GI
cancers, and no significant heterogeneity was found across studies.
It was also noted that, when limiting the pooled analysis to the
studies with high quality, the results were persistent and robust,
with the NQO1 609 T allele being significantly associated with the
increased risk of GI cancers. Publication bias was not observed in
this study. These findings suggest that the NQO1 609C.T
polymorphism may modify the risk of GI cancers.
Our findings have some biological plausibility, because NQO1
performs multiple functions within the cell. Conclusive evidence
suggests that NQO1 has a protective function in cellular defense
against the toxicity of electrophilic and oxidizing metabolites of
xenobiotic quinones [81]. In addition, its induction protects cells
against carcinogenesis [27,28,29,30,31,81]. Constitutive expres-
sion of NQO1 has been found in most human tissues, where its
expression is highly induced by various stimuli, including
antioxidants, oxidants, xenobiotics, heavy metals, UV light, and
Figure 3. Forest plot (Fixed effects model) describing the association of the NQO1 609C.T polymorphism with risk of
gastrointestinal (GI) cancers. The NQO1 609C.T polymorphism was associated with a modestly increased risk of GI cancers in a dominant model
(CT/TT vs. CC).
doi:10.1371/journal.pone.0030566.g003
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30566ionizing radiation [37]. It has been shown that NQO1 is
overexpressed in many human tumors, including cancers of the
lung, breasts, liver, esophagus, stomach, colon, pancreas, and
bladder [24,31,42,43,82,83,84,85]. The NQO1 knockout mice
were reported to exhibit marked increased sensitivity to 7,12-
dimethylbenz(a)anthracene (DMBA)- and benzo(a)pyrene (BP)-
induced skin carcinogenesis [86,87].
Human NQO1 is polymorphic [88], of which the NQO1 609C.T
polymorphism, in terms of its frequency and phenotypic conse-
quences, is most prominent and thus intensively studied. Our results
are consistent with the potentially altered biological functions of
NQO1 by the 609C.T polymorphism. Although the association of
the homozygous variant genotype (TT) with overall cancer risk did
not achieve statistical significance, the magnitude and direction for
association for GI cancers were persistent in both overall and some
subgroups in our meta-analysis. Because the frequency of the TT
genotype of the NQO1 609C.T polymorphism was low in the
published study populations, with 3.1% and 13.1% of the controls
being the TT homozygote in Caucasians and Asians, respectively,
we might not have sufficient statistical power to detect the weak
effect of this variant genotype on risk of GI cancers. Further studies
with larger sample sizes are warranted.
GI cancers represent a heterogeneous group of malignancies.
Except for some shared risk factors, different primary sites of GI
cancers have different risk factors and thus different etiologies. For
example, in addition to smoking and alcohol consumption, H.
Pylori infection is involved in stomach cancer and HBV/HCV
infection is involved in liver cancer, while dietary exposure to
heterocyclic amines (HCAs), nitrosamines, polycyclic aromatic
hydrocarbons (PAHs) derived from red meat and processed meat
is a key risk factor for colorectum cancer. Such etiologic
heterogeneity in GI cancers raises the possibility that the NQO1
Figure 4. Funnel plot analysis to detect publication bias. Each point represents an individual study for the indicated association.
doi:10.1371/journal.pone.0030566.g004
Table 4. False positive reporting probability values for associations between the NQO1 609C.T polymorphism and the risk of GI
cancers.
Genotype OR (95% CI) Prior probability
0.25 0.1 0.01 0.001 0.0001
All subjects
CT vs. CC 1.10 (1.01 – 1.19) 0.051 0.138 0.638 0.947 0.994
CT/TT vs. CC 1.11 (1.02 – 1.20) 0.026 0.074 0.469 0.899 0.989
Caucasians
CT vs. CC 1.13 (1.01 – 1.26) 0.088 0.225 0.762 0.970 0.997
CT/TT vs. CC 1.14 (1.02 – 1.26) 0.035 0.099 0.547 0.924 0.992
Colorectum cancer in Caucasians
CT/TT vs. CC 1.13 (1.00 – 1.28) 0.165 0.373 0.867 0.985 0.998
High quality of study
CT vs. CC 1.10 (1.00 – 1.22) 0.184 0.403 0.881 0.987 0.999
CT/TT vs. CC 1.11 (1.01 – 1.22) 0.088 0.224 0.761 0.970 0.997
doi:10.1371/journal.pone.0030566.t004
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30566polymorphism may be associated with specific types of GI cancers,
because NQO1 plays an important role in detoxifying dietary
carcinogenic compounds such as HCAs, PAHs and nitrosamines
[89]. Therefore, the functional NQO1 609 C.T polymorphism
resulting in decreased activity of NQO1 enzyme may increase risk
of colorectum cancer. Indeed, in the stratification analysis by
cancer site in Caucasians and Asians, significantly elevated risk
associated with the NQO1 609T allele was only found for
colorectal cancer among Caucasians but not in Asians. A previous
meta-analysis by Chao et al. [62] found an association between the
NQO1 609T allele and an increased risk for colorectal cancer (CT/
TT vs. CC: OR=1.18, 95% CI: 1.02 – 1.35) among 1637 cases
and 1854 controls in the Caucasian population, and this
association remained statistically significant in this expanded
meta-analysis that had included additional subjects (2410 cases
and 2676 controls in the Caucasian population). However, the
meta-analysis for the NQO1 609C.T polymorphism and
colorectal cancer risk was not performed in Asian population in
Chao’s study. We also did not find significant associations between
this SNP and risk of other cancer sites, such as cancers of the
esophagus, stomach, and pancreas either in Caucasians or in
Asians. This lack of significance could be due to either no effect of
this SNP on these cancer sites or limited statistical power to detect
such a weak association. In our meta-analysis, only two studies
with 316 cases and 341 controls for pancreatic cancer in
Caucasians, three studies with 375 cases and 1,000 controls for
gastric cancer and three studies with 916 cases and 1577 controls
for colorectum were conducted in Asians. Therefore, our results
should be interpreted with caution. Because the NQO1 609C.T
polymorphism is functional and potentially to be associated with
risk of cancer as shown in this meta-analysis, further larger studies
are needed, especially for non-colorectal GI cancers in Caucasians
and GI cancers in Asians.
Certain potential limitations exist in our meta-analysis. Firstly,
although the Begg’s test and Egger’s test did not show any
publication bias, selection bias could have occurred, because only
studies published in English were included in our meta-analysis.
Secondly, all the studies included in this meta-analysis were
hospital-based case-control studies. In this instance, the hospital-
based controls may not be representative of the general
population. Thirdly, the numbers of published studies were still
not sufficiently large for the analysis of the effect of the variant TT
genotype on risk of GI cancers and for some subgroups.
Furthermore, we were unable to perform further subgroup
analyses for a particular cancer site in different ethnic populations
due to a limited number of published studies available to be
included. For example, only one Caucasian study and one Asian
study for gastric cancer and liver cancer were available for this
meta-analysis, respectively. Fourthly, the FPRP analyses showed
that with the assumption of a prior probability of 0.1, the FPRP
values for the significant findings in overall comparisons and the
comparison in the dominant model in Caucasians were below 0.2,
providing some measures of robustness for our observations.
However, greater FPRP values were observed for the other
significant associations between the NQO1 609C.T polymor-
phism and risk of GI cancers, suggesting some possible bias in the
findings. Finally, due to lacking individual original data, we did not
take into account the other factors such as sex, ethnicity, smoking
and drinking status, that could modify the risk of estimate
[57,62,69], when we evaluated the effect of the NQO1 609 C.T
polymorphism on the risk of GI cancers. A more precise analysis
could have been conducted, if individual data were available.
Furthermore, gene-environment and gene-gene interactions
should also be considered in further studies.
In summary, despite the above-mentioned limitations, our
meta-analysis suggests that the minor allele T of the NQO1
609C.T polymorphism may be associated with a moderately
increased risk of GI cancers. Although the effect on cancer risk
may be modified by ethnicity and cancer sites, small sample sizes
in some subgroups suggest that future large and well-designed
studies in different ethnic populations and different sites of GI
cancers are needed to validate our findings.
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